167 related articles for article (PubMed ID: 2005390)
1. T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes.
Peace DJ; Chen W; Nelson H; Cheever MA
J Immunol; 1991 Mar; 146(6):2059-65. PubMed ID: 2005390
[TBL] [Abstract][Full Text] [Related]
2. Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21.
Abrams SI; Dobrzanski MJ; Wells DT; Stanziale SF; Zaremba S; Masuelli L; Kantor JA; Schlom J; Masuelle L [corrected to Masuelli L]
Eur J Immunol; 1995 Sep; 25(9):2588-97. PubMed ID: 7589131
[TBL] [Abstract][Full Text] [Related]
3. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
[TBL] [Abstract][Full Text] [Related]
4. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
[TBL] [Abstract][Full Text] [Related]
5. Overlapping epitopes encompassing a point mutation (12 Gly-->Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells.
Fossum B; Gedde-Dahl T; Hansen T; Eriksen JA; Thorsby E; Gaudernack G
Eur J Immunol; 1993 Oct; 23(10):2687-91. PubMed ID: 7691613
[TBL] [Abstract][Full Text] [Related]
6. Unconventional cytotoxic T lymphocyte recognition of synthetic peptides corresponding to residues 1-23 of Ras protein.
Yin L; Thomas C; Hsuan JJ; Stauss HJ
Eur J Immunol; 1994 Sep; 24(9):1988-92. PubMed ID: 8088318
[TBL] [Abstract][Full Text] [Related]
7. Mutant ras epitopes as targets for cancer vaccines.
Abrams SI; Hand PH; Tsang KY; Schlom J
Semin Oncol; 1996 Feb; 23(1):118-34. PubMed ID: 8607022
[TBL] [Abstract][Full Text] [Related]
8. Characterization of monoclonal antibodies specific to the activated ras p21 with aspartic acid at position 13.
La Vecchio JA; Hamer PJ; Ng SC; Trimpe KL; Carney WP
Oncogene; 1990 Aug; 5(8):1173-8. PubMed ID: 2202949
[TBL] [Abstract][Full Text] [Related]
9. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.
Kaumaya PT; Kobs-Conrad S; Seo YH; Lee H; VanBuskirk AM; Feng N; Sheridan JF; Stevens V
J Mol Recognit; 1993 Jun; 6(2):81-94. PubMed ID: 7508238
[TBL] [Abstract][Full Text] [Related]
10. T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA.
Gedde-Dahl T; Spurkland A; Fossum B; Wittinghofer A; Thorsby E; Gaudernack G
Eur J Immunol; 1994 Feb; 24(2):410-4. PubMed ID: 7507844
[TBL] [Abstract][Full Text] [Related]
11. T cell clones specific for p21 ras-derived peptides: characterization of their fine specificity and HLA restriction.
Gedde-Dahl T; Fossum B; Eriksen JA; Thorsby E; Gaudernack G
Eur J Immunol; 1993 Mar; 23(3):754-60. PubMed ID: 8449222
[TBL] [Abstract][Full Text] [Related]
12. Detection of transforming ras proteins containing leucine at position 61 by a new mouse monoclonal antibody, ras(53-69)Leu61.
Bizub D; Fischberg-Bender E; Heimer EP; Felix A; Skalka AM
Cancer Res; 1989 Nov; 49(22):6425-31. PubMed ID: 2680065
[TBL] [Abstract][Full Text] [Related]
13. Characterization of monoclonal antibody R256, specific for activated ras p21 with arginine at 12, and analysis of breast carcinoma of v-Harvey-ras transgenic mouse.
Pullano TG; Sinn E; Carney WP
Oncogene; 1989 Aug; 4(8):1003-8. PubMed ID: 2474786
[TBL] [Abstract][Full Text] [Related]
14. T cell recognition of a point mutation in the P21 Ras protein.
Yin L; Lowe P; Stauss HJ
Leukemia; 1993 Aug; 7 Suppl 2():S27-30. PubMed ID: 7689674
[TBL] [Abstract][Full Text] [Related]
15. Permissive recognition of a mycobacterial T-cell epitope: localization of overlapping epitope core sequences recognized in association with multiple major histocompatibility complex class II I-A molecules.
Harris DP; Vordermeier HM; Arya A; Moreno C; Ivanyi J
Immunology; 1995 Apr; 84(4):555-61. PubMed ID: 7790029
[TBL] [Abstract][Full Text] [Related]
16. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes.
Seliger B; Harders C; Wollscheid U; Staege MS; Reske-Kunz AB; Huber C
Exp Hematol; 1996 Sep; 24(11):1275-9. PubMed ID: 8862437
[TBL] [Abstract][Full Text] [Related]
17. Structural features of an antigen required for cellular interactions and for T cell activation in a MHC-restricted response.
Langton BC; Mackewicz CE; Wan AM; Andria ML; Benjamini E
J Immunol; 1988 Jul; 141(2):447-56. PubMed ID: 3260252
[TBL] [Abstract][Full Text] [Related]
18. Antibody to ras proteins in patients with colon cancer.
Takahashi M; Chen W; Byrd DR; Disis ML; Huseby ES; Qin H; McCahill L; Nelson H; Shimada H; Okuno K
Clin Cancer Res; 1995 Oct; 1(10):1071-7. PubMed ID: 9815896
[TBL] [Abstract][Full Text] [Related]
19. Subunit peptide cancer vaccines targeting activating mutations of the p21 ras proto-oncogene.
Triozzi PL; Stoner GD; Kaumaya PT
Biomed Pept Proteins Nucleic Acids; 1995; 1(3):185-92. PubMed ID: 9346851
[TBL] [Abstract][Full Text] [Related]
20. Functionally distinct agretopic and epitopic sites. Analysis of the dominant T cell determinant of moth and pigeon cytochromes c with the use of synthetic peptide antigens.
Fox BS; Chen C; Fraga E; French CA; Singh B; Schwartz RH
J Immunol; 1987 Sep; 139(5):1578-88. PubMed ID: 2442249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
